PolyPid (PYPD NASDAQ) stock market data APIs
$3.9542
-0.03(-0.8%)
as of December 19, 2025
Try our APIs with
free plan!
PolyPid Financial Data Overview
Price chart is built with
Anychart
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Prev. Close
3.9542
Open
3.9239
High
3.958
Low
3.9236
52 wk Range
2.3-4.07
Market Cap
66 040 K
Shares Outstanding
16 635 K
EPS
-0.37
Beta
1.494
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PolyPid data using free add-ons & libraries
Get PolyPid Fundamental Data
PolyPid Fundamental data includes:
- Net Revenue:
- EBITDA: -31 186 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.52
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PolyPid News
New
PolyPid Appoints Brooke Story As Chairman Of Board
(RTTNews) - PolyPid Ltd. (PYPD), a late-stage biopharma company, Tuesday announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's ...
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
PolyPid Ltd. Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE N...
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today an...
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following P...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
